TH Open (Apr 2024)
Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors
- Mark Goldin,
- Kolton Smith,
- Ioannis Koulas,
- Tungming Leung,
- Mayuri Ravi,
- Sanjit Parhar,
- Sejal Shah,
- Kayla Floyd,
- Lori Ohanesian,
- Rachel Bain,
- Daniella Defonte,
- Kanta Ochani,
- Amanda Lin,
- Bhumi Patel,
- Nikolaos Tsaftaridis,
- Jack Jnani,
- Alex C. Spyropoulos
Affiliations
- Mark Goldin
- Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States
- Kolton Smith
- Department of Medicine, Lenox Hill Hospital at Northwell Health, New York, New York, United States
- Ioannis Koulas
- Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States
- Tungming Leung
- Biostatistics Unit, Office of Academic Affairs, Northwell Health, Hempstead, New York, United States
- Mayuri Ravi
- Department of Medicine, North Shore University Hospital, Manhasset, New York, United States
- Sanjit Parhar
- Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States
- Sejal Shah
- Department of Medicine, Lenox Hill Hospital at Northwell Health, New York, New York, United States
- Kayla Floyd
- Department of Medicine, Lenox Hill Hospital at Northwell Health, New York, New York, United States
- Lori Ohanesian
- Clinical Pharmacy, Long Island Jewish Medical Center, New Hyde Park, New York, United States
- Rachel Bain
- Clinical Pharmacy, Long Island Jewish Valley Stream, Valley Stream, New York, United States
- Daniella Defonte
- Clinical Pharmacy, Glen Cove Hospital, Glen Cove, New York, United States
- Kanta Ochani
- Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States
- Amanda Lin
- Clinical Pharmacy, North Shore University Hospital, Manhasset, New York, United States
- Bhumi Patel
- Clinical Pharmacy, Glen Cove Hospital, Glen Cove, New York, United States
- Nikolaos Tsaftaridis
- Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States
- Jack Jnani
- Department of Medicine, North Shore University Hospital, Manhasset, New York, United States
- Alex C. Spyropoulos
- ORCiD
- Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States
- DOI
- https://doi.org/10.1055/a-2306-0804
- Journal volume & issue
-
Vol. 08,
no. 02
pp. e209 – e215
Abstract
Background Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Keywords
